Cargando…

Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer

Volumetric-modulated arc therapy (VMAT) is a widespread intensity-modulated radiation therapy (IMRT) method, however, VMAT requires adaptation of the radiation treatment planning system (RTPS) and linear accelerator (linac); these upgrades are quite expensive. The Smart Arc of Pinnacle(3) (Philips),...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatanaka, Shogo, Tamaki, Seiichi, Endo, Haruna, Mizuno, Norifumi, Nakamura, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099990/
https://www.ncbi.nlm.nih.gov/pubmed/24522268
http://dx.doi.org/10.1093/jrr/rrt232
_version_ 1782326589698080768
author Hatanaka, Shogo
Tamaki, Seiichi
Endo, Haruna
Mizuno, Norifumi
Nakamura, Naoki
author_facet Hatanaka, Shogo
Tamaki, Seiichi
Endo, Haruna
Mizuno, Norifumi
Nakamura, Naoki
author_sort Hatanaka, Shogo
collection PubMed
description Volumetric-modulated arc therapy (VMAT) is a widespread intensity-modulated radiation therapy (IMRT) method, however, VMAT requires adaptation of the radiation treatment planning system (RTPS) and linear accelerator (linac); these upgrades are quite expensive. The Smart Arc of Pinnacle(3) (Philips), which is the software used in VMAT calculations, can select constant dose rate (CDR) mode. This approach has a low initial cost because the linac upgrade is not required. The objective of this study was to clarify the utility of CDR mode for prostate IMRT. Pinnacle(3) and Clinac 21EX linac (Varian, 10 MV X-rays) were used for planning. The plans were created for 28 patients using a fixed multi-field IMRT (f-IMRT), VMAT and CDR techniques. The dose distribution results were classified into three groups: optimal, suboptimal and reject. For the f-IMRT, VMAT and CDR results, 25, 26 and 21 patients were classified as ‘optimal’, respectively. Our results show a significant reduction in the achievement rate of ‘optimal’ for a CDR when the bladder volume is <100 cm(3). The total numbers of monitoring units (MUs) (average ± 1σ) were 469 ± 53, 357 ± 35 and 365 ± 33; the average optimization times were ∼50 min, 2 h and 2 h 40 min, and the irradiation times were ∼280 s, 60 s and 110 s, respectively. CDR can reduce the total MUs and irradiation time compared with f-IMRT, and CDR has a lower initial cost compared with VMAT. Thus, for institutions that do not currently perform VMAT, CDR is a useful option. Additionally, in the context of patient identification, bladder volume may be useful.
format Online
Article
Text
id pubmed-4099990
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-40999902014-08-12 Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer Hatanaka, Shogo Tamaki, Seiichi Endo, Haruna Mizuno, Norifumi Nakamura, Naoki J Radiat Res Oncology Volumetric-modulated arc therapy (VMAT) is a widespread intensity-modulated radiation therapy (IMRT) method, however, VMAT requires adaptation of the radiation treatment planning system (RTPS) and linear accelerator (linac); these upgrades are quite expensive. The Smart Arc of Pinnacle(3) (Philips), which is the software used in VMAT calculations, can select constant dose rate (CDR) mode. This approach has a low initial cost because the linac upgrade is not required. The objective of this study was to clarify the utility of CDR mode for prostate IMRT. Pinnacle(3) and Clinac 21EX linac (Varian, 10 MV X-rays) were used for planning. The plans were created for 28 patients using a fixed multi-field IMRT (f-IMRT), VMAT and CDR techniques. The dose distribution results were classified into three groups: optimal, suboptimal and reject. For the f-IMRT, VMAT and CDR results, 25, 26 and 21 patients were classified as ‘optimal’, respectively. Our results show a significant reduction in the achievement rate of ‘optimal’ for a CDR when the bladder volume is <100 cm(3). The total numbers of monitoring units (MUs) (average ± 1σ) were 469 ± 53, 357 ± 35 and 365 ± 33; the average optimization times were ∼50 min, 2 h and 2 h 40 min, and the irradiation times were ∼280 s, 60 s and 110 s, respectively. CDR can reduce the total MUs and irradiation time compared with f-IMRT, and CDR has a lower initial cost compared with VMAT. Thus, for institutions that do not currently perform VMAT, CDR is a useful option. Additionally, in the context of patient identification, bladder volume may be useful. Oxford University Press 2014-07 2014-02-11 /pmc/articles/PMC4099990/ /pubmed/24522268 http://dx.doi.org/10.1093/jrr/rrt232 Text en © The Author 2014. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oncology
Hatanaka, Shogo
Tamaki, Seiichi
Endo, Haruna
Mizuno, Norifumi
Nakamura, Naoki
Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title_full Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title_fullStr Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title_full_unstemmed Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title_short Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer
title_sort utility of smart arc cdr for intensity-modulated radiation therapy for prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099990/
https://www.ncbi.nlm.nih.gov/pubmed/24522268
http://dx.doi.org/10.1093/jrr/rrt232
work_keys_str_mv AT hatanakashogo utilityofsmartarccdrforintensitymodulatedradiationtherapyforprostatecancer
AT tamakiseiichi utilityofsmartarccdrforintensitymodulatedradiationtherapyforprostatecancer
AT endoharuna utilityofsmartarccdrforintensitymodulatedradiationtherapyforprostatecancer
AT mizunonorifumi utilityofsmartarccdrforintensitymodulatedradiationtherapyforprostatecancer
AT nakamuranaoki utilityofsmartarccdrforintensitymodulatedradiationtherapyforprostatecancer